A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
Pfizer
Bristol-Myers Squibb
ModernaTX, Inc.
Vivace Therapeutics, Inc
Bristol-Myers Squibb
Neonc Technologies, Inc.
Bristol-Myers Squibb
Sanofi
Bristol-Myers Squibb
Bristol-Myers Squibb
BioInvent International AB
Bristol-Myers Squibb
TriSalus Life Sciences, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Vyriad, Inc.
Bristol-Myers Squibb
TCR2 Therapeutics
Incyte Corporation
Hoffmann-La Roche
CytomX Therapeutics
Biogen
Bristol-Myers Squibb
Bristol-Myers Squibb
Intensity Therapeutics, Inc.
Bristol-Myers Squibb
Ultimovacs ASA
Immodulon Therapeutics Ltd
Jounce Therapeutics, Inc.
Amgen
Bristol-Myers Squibb
Bristol-Myers Squibb
Gritstone bio, Inc.
Gritstone bio, Inc.
Bristol-Myers Squibb
Jounce Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Bristol-Myers Squibb
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
AbbVie
Lumos Pharma
Incyte Corporation
Celldex Therapeutics